HCA Healthcare (HCA) is trading down at $468.50 (-0.41%) on NYSE/NASDAQ, as of the latest quote. It is a S&P 500 constituent in the Health Care sector.
Analyst price targets on HCA
One firm's current price target on HCA Healthcare: $435 — 7% below the current $469. Each is tracked to its date and scored the same way a member's call is.
- KeyBanc Capital Markets $390 → $435 by Jul 2027 Jul 27, 2026 via Investing.com · KeyBanc Capital Markets's track record
Targets published by research firms, extracted from the news, checked against independent reporting, and linked to their source. Where a firm did not state a horizon the target is tracked as 12 months, the industry convention; the rows where the firm set its own horizon are marked. Reported here as facts about what was published — not recommendations from Dalsna Finance, and no firm listed is affiliated with this site.
HCA Healthcare revenue & net income history (FY2016–FY2025)
| FY2016Dec 2016 | FY2017Dec 2017 | FY2018Dec 2018 | FY2019Dec 2019 | FY2020Dec 2020 | FY2021Dec 2021 | FY2022Dec 2022 | FY2023Dec 2023 | FY2024Dec 2024 | FY2025Dec 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | $41.5B | $43.6B | $46.7B | $51.3B | $51.5B | $58.8B | $60.2B | $65.0B | $70.6B | $75.6B |
| Growth (year over year) | — | +5.1% | +7.0% | +10.0% | +0.4% | +14.0% | +2.5% | +7.9% | +8.7% | +7.1% |
| Net income | $2.89B | $2.22B | $3.79B | $3.50B | $3.75B | $6.96B | $5.64B | $5.24B | $5.76B | $6.78B |
| Net margin | 7.0% | 5.1% | 8.1% | 6.8% | 7.3% | 11.8% | 9.4% | 8.1% | 8.2% | 9.0% |
| EPS (diluted) | $7.30 | $5.95 | $10.66 | $10.07 | $10.93 | $21.16 | $19.15 | $18.97 | $22.00 | $28.33 |
| Balance sheet | ||||||||||
| Cash and equivalents | $646.0M | $732.0M | $502.0M | $621.0M | $1.79B | $1.45B | $908.0M | $935.0M | $1.93B | $1.04B |
| Total assets | $33.8B | $36.6B | $39.2B | $45.1B | $47.5B | $50.7B | $52.4B | $56.2B | $59.5B | $60.7B |
| Total liabilities | $39.4B | $41.6B | $42.1B | $45.6B | $44.6B | $49.3B | $52.5B | $55.2B | $59.0B | $63.5B |
| Long-term debt | $31.2B | $32.9B | $32.0B | $33.6B | $30.8B | $34.3B | $37.7B | $37.2B | $38.3B | $41.6B |
| Shareholders' equity | −$7.30B | −$6.81B | −$4.95B | −$2.81B | $572.0M | −$933.0M | −$2.77B | −$1.77B | −$2.50B | −$6.03B |
| Cash flow | ||||||||||
| Operating cash flow | $5.65B | $5.43B | $6.76B | $7.60B | $9.23B | $8.96B | $8.52B | $9.43B | $10.5B | $12.6B |
| Capital expenditure | $2.76B | $3.02B | $3.57B | $4.16B | $2.83B | $3.58B | $4.39B | $4.74B | $4.88B | $4.94B |
| Free cash flow | $2.89B | $2.41B | $3.19B | $3.44B | $6.40B | $5.38B | $4.13B | $4.69B | $5.64B | $7.69B |
| Dividends paid | — | $0 | $487.0M | $550.0M | $153.0M | $624.0M | $653.0M | $661.0M | $690.0M | $679.0M |
| Share buybacks | $2.75B | $2.05B | $1.53B | $1.03B | $441.0M | $8.21B | $7.00B | $3.81B | $6.04B | $10.1B |
| Q2 FY24Jun 2024 | Q3 FY24Sep 2024 | Q4 FY24†Dec 2024 | Q1 FY25Mar 2025 | Q2 FY25Jun 2025 | Q3 FY25Sep 2025 | Q4 FY25†Dec 2025 | Q1 FY26Mar 2026 | |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $17.5B | $17.5B | $18.3B | $18.3B | $18.6B | $19.2B | $19.5B | $19.1B |
| Growth (year over year) | +10.3% | +7.9% | +5.7% | +5.7% | +6.4% | +9.6% | +6.7% | +4.3% |
| Net income | $1.46B | $1.27B | $1.44B | $1.61B | $1.65B | $1.64B | $1.88B | $1.62B |
| Net margin | 8.4% | 7.3% | 7.9% | 8.8% | 8.9% | 8.6% | 9.6% | 8.5% |
| EPS (diluted) | $5.53 | $4.88 | $5.66 | $6.45 | $6.83 | $6.96 | $8.09 | $7.15 |
| Balance sheet | ||||||||
| Cash and equivalents | $831.0M | $2.89B | $1.93B | $1.06B | $939.0M | $997.0M | $1.04B | $940.0M |
| Total assets | $57.4B | $59.5B | $59.5B | $59.8B | $59.5B | $59.7B | $60.7B | $61.5B |
| Total liabilities | $56.0B | $58.7B | $59.0B | $60.2B | $60.8B | $61.9B | $63.5B | $64.4B |
| Long-term debt | $36.3B | $38.3B | $38.3B | $41.1B | $39.4B | $38.4B | $41.6B | $39.5B |
| Shareholders' equity | −$1.60B | −$2.18B | −$2.50B | −$3.52B | −$4.39B | −$5.33B | −$6.03B | −$6.30B |
| Cash flow | ||||||||
| Operating cash flow | $1.97B | $3.52B | $2.56B | $1.65B | $4.21B | $4.42B | $2.36B | $2.01B |
| Capital expenditure | $1.28B | $1.19B | $1.28B | $991.0M | $1.18B | $1.29B | $1.49B | $1.12B |
| Free cash flow | $690.0M | $2.32B | $1.27B | $660.0M | $3.03B | $3.13B | $870.0M | $895.0M |
| Dividends paid | $171.0M | $169.0M | $165.0M | $180.0M | $171.0M | $166.0M | $162.0M | $183.0M |
| Share buybacks | $1.37B | $1.79B | $1.70B | $2.51B | $2.50B | $2.50B | $2.56B | $1.57B |
From HCA Healthcare's 10-K and 10-Q filings with the SEC; its fiscal year ends in December. Each period shows the latest figure the company has reported for it, including restatements. Net margin is our own calculation from those reported figures (net income ÷ revenue); it is left blank where revenue is zero or missing. † Quarter derived from the company's year-to-date or full-year totals. Filings on SEC EDGAR →
About HCA Healthcare
HCA Healthcare, Inc. is an American global for-profit operator of health care facilities that was founded in 1968. It is based in Nashville, Tennessee, and, as of May 2020, owned and operated 186 hospitals and approximately 2,400 sites of care, including surgery centers, freestanding emergency rooms, urgent care centers and physician clinics in 20 states and the United Kingdom. As of 2024, HCA Healthcare is ranked #61 on the Fortune 500 rankings of the largest United States corporations by total revenue. In the 1990s, the company engaged in illegal accounting and other crimes that resulted in the payment of more than $2 billion in federal fines and other penalties, and the dismissal of the CEO Rick Scott by the board of directors.
Source: Wikipedia — HCA Healthcare
- Headquarters
- Nashville, Tennessee From SEC filings, Oct 2026
Recent News (20)
-
HCA Healthcare Is Too Healthy To Downgrade (NYSE:HCA) HCA Healthcare Is Too Healthy To Downgrade (NYSE:HCA) Seeking Alpha
-
Relay Robotics Brings Autonomous Delivery to HCA Florida JFK Hospital New deployment demonstrates how autonomous delivery robots can integrate with complex hospital infrastructure while supporting hospital teams and patient care SAN JOSE, Calif., Sept. 30, 2026 /PRNewsw…
-
SOLIS MAMMOGRAPHY AND HCA HEALTHCARE CHARLESTON PARTNER TO EXPAND BREAST HEALTH SERVICES IN SOUTH CAROLINA Partnership Marks Solis Mammography's First Location in South Carolina ADDISON, Texas, Sept. 29, 2026 /PRNewswire/ -- Solis Mammography, the nation's largest independent provider of specialized breast…
-
Washington State Health Care Authority Selects REI Systems' GovGrants® Amid Historic Investment in Rural Health Configurable platform will help HCA manage complex health funding with greater visibility, accountability, and impact. STERLING, Va., Sept. 29, 2026 /PRNewswire/ -- REI Systems, a leading provider of …
-
-
BMO starts HCA Healthcare stock at Outperform on growth outlook
BMO starts HCA Healthcare stock at Outperform on growth outlook
-
HCA Healthcare (HCA) Acquires a Healthcare College. Can Training Capacity Improve Staffing?
HCA Healthcare (HCA) Acquires a Healthcare College. Can Training Capacity Improve Staffing?
-
HCA Healthcare Sees Solid Demand as Exchange Headwinds Pressure 2026 Outlook
HCA Healthcare Sees Solid Demand as Exchange Headwinds Pressure 2026 Outlook
-
Alluvium Increases HCA Healthcare (HCA) Holdings After Its 17.5% Selloff
Alluvium Increases HCA Healthcare (HCA) Holdings After Its 17.5% Selloff
-
HCA Healthcare at wells fargo healthcare conference: growth offsets policy hit
HCA Healthcare at wells fargo healthcare conference: growth offsets policy hit
-
Is HCA Healthcare Stock Underperforming the Nasdaq?
Is HCA Healthcare Stock Underperforming the Nasdaq?
-
-
HCA Healthcare (HCA) Navigates Patient Volume Challenges While Reporting Growth
HCA Healthcare (HCA) Navigates Patient Volume Challenges While Reporting Growth
-
HCA Healthcare Inc Stock (HCA) Moved Up by 5.35% on Aug 21: Drivers Behind the Movement HCA Healthcare Inc Stock (HCA) Moved Up by 5.35% on Aug 21: Drivers Behind the Movement TradingKey
-
Do Wall Street Analysts Like HCA Healthcare Stock?
Do Wall Street Analysts Like HCA Healthcare Stock?
-
Could HCA Healthcare, Inc. (HCA) Stock Rebound After Guidance Cuts and Payer Pressure?
Could HCA Healthcare, Inc. (HCA) Stock Rebound After Guidance Cuts and Payer Pressure?
-
HCA Healthcare’s former CFO on the role of partnerships in health HCA Healthcare’s former CFO on the role of partnerships in health
-
Market Digest: NVO, BKNG, NFG, PH, REG, HCA, CLF, SNDK, APP
Market Digest: NVO, BKNG, NFG, PH, REG, HCA, CLF, SNDK, APP
-
-
HCA Healthcare names new chief clinical officer, ambulatory head
HCA Healthcare names new chief clinical officer, ambulatory head
More Health Care stocks
- ELV Elevance Health
- EW Edwards Lifesciences
- GEHC GE HealthCare
- GILD Gilead Sciences
- HSIC Henry Schein
- HUM Humana
- IDXX Idexx Laboratories
- ILMN Illumina